(Q40872467)

24 September 2017

title

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial (English)

1 reference

multicenter clinical trial

24 September 2017

0 references

0 references

0 references

0 references

1 reference

ORCID Public Data File 2021

author name string

Michael Gnant

1

1 reference

24 September 2017

Georg Pfeiler

2

1 reference

24 September 2017

Peter C Dubsky

3

1 reference

24 September 2017

Michael Hubalek

4

1 reference

24 September 2017

Richard Greil

5

1 reference

24 September 2017

Raimund Jakesz

6

1 reference

24 September 2017

Viktor Wette

7

1 reference

24 September 2017

Marija Balic

8

1 reference

24 September 2017

Ferdinand Haslbauer

9

1 reference

24 September 2017

Elisabeth Melbinger

10

1 reference

24 September 2017

Vesna Bjelic-Radisic

11

1 reference

24 September 2017

Silvia Artner-Matuschek

12

1 reference

24 September 2017

Florian Fitzal

13

1 reference

24 September 2017

Christian Marth

14

1 reference

24 September 2017

Paul Sevelda

15

1 reference

24 September 2017

Brigitte Mlineritsch

16

1 reference

24 September 2017

Günther G Steger

17

1 reference

24 September 2017

Diether Manfreda

18

1 reference

24 September 2017

Ruth Exner

19

1 reference

24 September 2017

Daniel Egle

20

1 reference

24 September 2017

Jonas Bergh

21

1 reference

24 September 2017

Franz Kainberger

22

1 reference

24 September 2017

Susan Talbot

23

1 reference

24 September 2017

Douglas Warner

24

1 reference

24 September 2017

Christian Fesl

25

1 reference

24 September 2017

Christian F Singer

26

1 reference

24 September 2017

Austrian Breast and Colorectal Cancer Study Group

27

1 reference

24 September 2017

language of work or name

English

0 references

publication date

31 May 2015

1 reference

24 September 2017

1 reference

24 September 2017

volume

386

1 reference

24 September 2017

issue

9992

1 reference

24 September 2017

page(s)

433-443

1 reference

Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Systematic review of bone health in older women treated with aromatase inhibitors for early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Increased fracture rate in women with breast cancer: a review of the hidden risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Role of bisphosphonates in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Aromatase inhibitors-induced bone loss in early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Vertebral fracture assessment using a semiquantitative technique.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

St. Gallen 2013: brief preliminary summary of the consensus discussion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Breaking away: high fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Cancer-associated bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Denosumab in postmenopausal women with low bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Labor costs and economic impact of a primary care clinical pharmacy service on postfracture care in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

Breast-cancer adjuvant therapy with zoledronic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2960995-3

7 January 2021

10.1016/S0140-6736(15)60995-3

Identifiers

DOI

1 reference

24 September 2017

1 reference